Experienced in Hemosiderosis

Dr. Joseph Z. Ye

Oncology
11311 Bridgeport Way SW, Suites 302 And 303, 
Lakewood, WA 
Accepting New Patients
Offers Telehealth
Experienced in Hemosiderosis
11311 Bridgeport Way SW, Suites 302 And 303, 
Lakewood, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joseph Ye is an Oncologist in Lakewood, Washington. Dr. Ye is rated as an Experienced provider by MediFind in the treatment of Hemosiderosis. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Familial Colorectal Cancer, Bone Marrow Aspiration, and Endoscopy. Dr. Ye is currently accepting new patients.

His clinical research consists of participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in WA
Hospital Affiliations
Capital Medical Center
Mason General Hospital & Family Of Clinics
Summit Pacific Medical Center
Providence Centralia Hospital
Providence St Peter Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Coordinated Care
  • HMO
  • MANAGED MEDICAID PLAN
Group Health Cooperative
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Lifewise

Accepted plan types not found. Please verify directly with the provider.

Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
PacificSource
  • PPO
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

Panacea Oncology - Lakewood
11311 Bridgeport Way SW, Suites 302 And 303, Lakewood, WA 98499

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: January 21, 2026
Intervention Type: Drug, Device
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 3
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Enrollment Status: Terminated
Publish Date: August 28, 2025
Intervention Type: Drug
Study Drugs: Brentuximab, Doxorubicin, Vinblastine, Dacarbazine, Nivolumab, Filgrastim
Study Phase: Phase 2
Open-label, Single-Arm, Phase 2 Study of Oral HDAC-inhibitor Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (FORERUNNER)
Open-label, Single-Arm, Phase 2 Study of Oral HDAC-inhibitor Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (FORERUNNER)
Enrollment Status: Active_not_recruiting
Publish Date: April 10, 2025
Intervention Type: Drug
Study Drug: Abexinostat
Study Phase: Phase 2
A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-2)
A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-2)
Enrollment Status: Completed
Publish Date: August 29, 2023
Intervention Type: Drug
Study Drug: Loncastuximab tesirine
Study Phase: Phase 2
A Randomized Phase 2 Study of Abemaciclib (LY2835219) Versus Docetaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
A Randomized Phase 2 Study of Abemaciclib (LY2835219) Versus Docetaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
Enrollment Status: Completed
Publish Date: August 13, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: December 09, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
Randomized Phase 2 Trial Evaluating Alternative Ramucirumab Doses in Combination With Paclitaxel in Second-Line Metastatic or Locally Advanced, Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma
Randomized Phase 2 Trial Evaluating Alternative Ramucirumab Doses in Combination With Paclitaxel in Second-Line Metastatic or Locally Advanced, Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Completed
Publish Date: June 17, 2020
Intervention Type: Drug
Study Phase: Phase 2
An Open Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) in Combination With RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) Compared With RCHOP Alone as Frontline Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Grade 3b
An Open Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) in Combination With RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) Compared With RCHOP Alone as Frontline Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Grade 3b
Enrollment Status: Terminated
Publish Date: March 11, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials
Similar Doctors
Advanced in Hemosiderosis
Dr. Weiqiang Gao
Hematology Oncology | Hematology | Oncology
Advanced in Hemosiderosis
Dr. Weiqiang Gao
Hematology Oncology | Hematology | Oncology

Valley Medical Group-Renton

3915 Talbot Rd S, Suite 300, 
Renton, WA 
 (44.3 miles away)
425-656-5570
Languages Spoken:
English, Mandarin
See accepted insurances
Accepting New Patients
Offers Telehealth

Weiqiang Gao is a Hematologist Oncology specialist and a Hematologist in Renton, Washington. Dr. Gao is rated as an Advanced provider by MediFind in the treatment of Hemosiderosis. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and B-Cell Lymphoma. Dr. Gao is currently accepting new patients.

Advanced in Hemosiderosis
Dr. Michelle M. Zhang
Hematology Oncology | Hematology | Oncology
Advanced in Hemosiderosis
Dr. Michelle M. Zhang
Hematology Oncology | Hematology | Oncology

Valley Medical Group-Renton

3915 Talbot Rd S, Suite 200, 
Renton, WA 
 (44.3 miles away)
425-690-3400
Languages Spoken:
English, Hindi, Mandarin, Punjabi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Michelle Zhang is a Hematologist Oncology specialist and a Hematologist in Renton, Washington. Dr. Zhang is rated as a Distinguished provider by MediFind in the treatment of Hemosiderosis. Her top areas of expertise are Paget Disease of the Breast, Anal Cancer, Inflammatory Breast Cancer, Small Cell Lung Cancer (SCLC), and Bone Marrow Aspiration. Dr. Zhang is currently accepting new patients.

Experienced in Hemosiderosis
Dr. Prakash Thapaliya
Hematology Oncology | Oncology | Hematology
Experienced in Hemosiderosis
Dr. Prakash Thapaliya
Hematology Oncology | Oncology | Hematology

Kaiser Foundation Health Plan Of Washington

700 Lilly Rd Ne, 
Olympia, WA 
 (5.3 miles away)
360-923-7000
Languages Spoken:
English, Arabic, Filipino, Hindi, Japanese, Korean, Nepali, Punjabi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Prakash Thapaliya is a Hematologist Oncology specialist and an Oncologist in Olympia, Washington. Dr. Thapaliya is rated as an Advanced provider by MediFind in the treatment of Hemosiderosis. His top areas of expertise are Multiple Myeloma, Familial Colorectal Cancer, Breast Cancer, Paget Disease of the Breast, and Bone Marrow Aspiration. Dr. Thapaliya is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ye's expertise for a condition
ConditionClose
    View All 9 Distinguished Conditions
    View All 25 Advanced Conditions
    View All 97 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile